Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Alberto Lleó,Henrik Zetterberg,Jordi Pegueroles,Thomas K. Karikari,María Carmona-Iragui,Nicholas J. Ashton,Victor Montal,Isabel Barroeta,Juan Lantero-Rodríguez,Laura Videla,Miren Altuna,Bessy Benejam,Susana Fernandez,Silvia Valldeneu,Diana Garzón,Alexandre Bejanin,Maria Florencia Iulita,Valle Camacho,Santiago Medrano-Martorell,Olivia Belbin,Jordi Clarimon,Sylvain Lehmann,Daniel Alcolea,Rafael Blesa,Kaj Blennow,Juan Fortea

DOI: https://doi.org/10.1038/s41467-021-24319-x

IF: 16.6

2021-07-14

Nature Communications

Abstract:Abstract Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer’s disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73–0.87] and 0.92 [95% CI 0.89–0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.

multidisciplinary sciences